Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Priority to ARP020102745priorityCriticalpatent/AR034836A1/en
Publication of AR034836A1publicationCriticalpatent/AR034836A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere sal de mono-clorhidrato de 2,5-diona-3-(1-metil-1H-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1H-indol-3-il]-1H-pirrol cristalino, una formulación farmacéutica que contiene dicha sal y los métodos para tratar cáncer y para inhibir el desarrollo de tumores utilizando dicha sal.The present invention relates to 2,5-dione-3- (1-methyl-1H-indol-3-yl) -4- [1- (pyridin-2-ylmethyl) piperidin-4-yl monohydrochloride salt ] -1H-indole-3-yl] -1H-crystalline pyrrole, a pharmaceutical formulation containing said salt and methods for treating cancer and for inhibiting the development of tumors using said salt.